CRAIGIN SHIMMENS: Open Payments
NPI 1871215897 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,556 in 115 payments from 38 companies in 2025. Trend: 2023 $2,472 · 2024 $2,530 · 2025 $2,556
Food & beverage: $2,556
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $352 |
| AstraZeneca Pharmaceuticals LP | 11 | $253 |
| Janssen Biotech, Inc. | 10 | $219 |
| Merck Sharp & Dohme LLC | 11 | $188 |
| PFIZER INC. | 9 | $148 |
| Novocure Inc. | 1 | $143 |
| ABBVIE INC. | 5 | $105 |
| Myriad Genetic Laboratories, Inc. | 1 | $105 |
| Daiichi Sankyo Inc. | 4 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $86 |
Products named: KEYTRUDA, PLUVICTO, Optune Lua (NovoTTF-200T), MYRISK, ENHERTU, DARZALEX, Zoladex, Lenvima.
Industry payments across MO — which companies pay providers there.
